EA201891687A9 - Новые замещённые производные цианиндолина в качестве nik-ингибиторов - Google Patents
Новые замещённые производные цианиндолина в качестве nik-ингибиторовInfo
- Publication number
- EA201891687A9 EA201891687A9 EA201891687A EA201891687A EA201891687A9 EA 201891687 A9 EA201891687 A9 EA 201891687A9 EA 201891687 A EA201891687 A EA 201891687A EA 201891687 A EA201891687 A EA 201891687A EA 201891687 A9 EA201891687 A9 EA 201891687A9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diseases
- cyanindoline
- derivatives
- new substituted
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к фармацевтическим агентам, пригодным для лечения и/или профилактики млекопитающего, и, в частности, к ингибиторам индуцируемой сигнальным путём NF-κВ киназы (NIK - известной также как MAP3K14), пригодным для лечения заболеваний, таких как рак, воспалительные заболевания, метаболические расстройства и аутоиммунные заболевания. Данное изобретение предусматривает также фармацевтические композиции, содержащие такие соединения, и применение таких соединений или фармацевтических композиций для профилактики или лечения заболеваний, таких как рак, воспалительные заболевания, метаболические расстройства, включая ожирение и диабет, и аутоиммунные заболевания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16159651 | 2016-03-10 | ||
PCT/EP2017/051150 WO2017125530A1 (en) | 2016-01-22 | 2017-01-20 | New substituted cyanoindoline derivatives as nik inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201891687A1 EA201891687A1 (ru) | 2019-06-28 |
EA201891687A9 true EA201891687A9 (ru) | 2020-01-15 |
EA037358B1 EA037358B1 (ru) | 2021-03-17 |
Family
ID=55521629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891687A EA037358B1 (ru) | 2016-03-10 | 2017-01-20 | Новые замещённые производные цианиндолина в качестве nik-ингибиторов |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA037358B1 (ru) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002079197A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
AU2009263037B2 (en) * | 2008-06-26 | 2011-10-06 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
-
2017
- 2017-01-20 EA EA201891687A patent/EA037358B1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EA037358B1 (ru) | 2021-03-17 |
EA201891687A1 (ru) | 2019-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
EA201792047A1 (ru) | Новые соединения | |
EA201790908A1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201790904A1 (ru) | Новые производные пиразола в качестве ингибиторов nik | |
EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
EA201790688A1 (ru) | Новые соединения в качестве ингибиторов nik | |
EA201790528A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
EA201592033A1 (ru) | 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА | |
MX371017B (es) | Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma. | |
EA201790907A1 (ru) | Новые производные пиразолопиримидина в качестве ингибиторов nik | |
EA201690657A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 3-(1H-ПИРАЗОЛ-4-ИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK | |
EA201690645A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK | |
EA201692470A1 (ru) | Фармацевтические комбинации | |
EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
MX2019014665A (es) | Nuevos derivados de azaindolina sustituida como inhibidores de nik. | |
EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
EA201500737A1 (ru) | Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов | |
EA202092446A1 (ru) | ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34 | |
EA201891687A9 (ru) | Новые замещённые производные цианиндолина в качестве nik-ингибиторов | |
EA201992793A1 (ru) | Ингибиторы протеинкиназ | |
EA202092082A1 (ru) | Соединения аминопиразиндиола как ингибиторы pi3k- | |
EA202092239A1 (ru) | Ингибиторы mcl-1 |